Our Activities

Fully-integrated pharmaceuticals

Teva's scope of activity extends to many facets of the industry, with a primary focus on the manufacturing and marketing of products in the following categories:

Human pharmaceuticals

Teva produces generic drugs in all major therapeutics and steriles in a variety of dosage forms, from tablets and capsules to ointments, creams and liquids.
In addition, Teva manufactures innovative drugs in niche markets where it has a relative advantage in research and development.

Active Pharmaceutical Ingredients (API)

Teva competitively distributes its API to manufacturers worldwide as well as supports its own pharmaceutical production. These activities, which comprise the core businesses of the company, account for 90% of Teva's total sales.

Generic pharmaceuticals - A comprehensive portfolio

Teva believes that its product diversity will continue to be of strategic significance, paralleling the needs of an emerging and dynamically evolving generic industry deeply affected by trends of consolidation among managed care providers, large pharmacy chains, wholesalers and other large-scale buyers. Teva Pharmaceuticals USA, the company's wholly-owned American subsidiary, is the jewel in the crown of Teva's international efforts in the generic pharmaceuticals arena and one of the most successful manufacturers and distributors of generic drugs in the U.S.
Teva USA is an integral part of Teva North America which encompasses the USA and Canada.
The company's impressive line offers the discerning American consumer an extensive portfolio of competitively priced products in diverse dosage forms. In 2004, Teva acquired Sicor which combined Teva's capabilities and knowledge in the solid dose generic drug franchise with Sicor's expertise in generic injectables.

Teva's forays into the European market include the acquisitions of the Dutch industry heavyweight Pharmachemie B.V., Teva Pharmaceuticals Germany GmbH (formerly GRY-Pharm), Teva UK Limited (formerly APS/Berk) in the UK, Teva Pharmaceutical Works Ltd. in Hungary (formerly Biogal) and others. Through these acquisitions, Teva has successfully established a broad network of subsidiaries across Europe, each attuned to the specific needs of its local customer base.

In 2006, Teva acquired IVAX which expanded product lines in generics, including a significant respiratory business, and a rich pipeline of generic and proprietary products in the areas of respiratory, CNS and oncology. The company will now offer the widest range of cost-effective pharmaceuticals, both generic and branded, to consumers, customers, and healthcare providers.

R&D - Innovation at the core
Teva's innovative products are developed for specialized markets with the current focus on neurological disorders and auto-immune diseases. Maintaining ongoing collaborative efforts with Israel's major universities, hospitals and research institutes is an important core element of Teva's approach to innovative Research and Development. Currently, Teva has novel treatments for MS, Parkinson's Disease (PD), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS) and other CNS indications as well as Systemic Lupus Erythematosus in clinical research phases.

Copaxone® - A breakthrough treatment offers hope

Copaxone®, a proprietary branded product used for the treatment of multiple sclerosis, was developed by Teva's R&D team and marks an important milestone in the company's development as it expands its activities to include innovative products. Copaxone® has been approved for marketing in 47 countries worldwide, including the United States, Israel, Canada, 22 European Union Countries including the new accessors, Switzerland, Australia, Russia, Brazil, and Argentina.
This is the first non-steroidal, non-interferon agent for treating patients with relapsing-remitting MS - a major breakthrough in the treatment of this devastating disease.

Azilect® (rasagiline) for Parkinson's Disease
Azilect® is a new treatment for Parkinson's Disease (PD), both as monotherapy, in early disease , and as an adjunct therapy to levodopa in the more advanced stages of PD. It is a potent, second generation, irreversible monoamine oxidase type B (MAO-B) inhibitor. Azilect combines efficacy with a convenient once-daily dosing regimen, no need for titration and a favourable side effect profile. Thus, Azilect® represents a significant therapeutic advance in the quest to improve PD treatment throughout the course of the disease, offering patients a simple option to the complex treatment of the disease. Launched in Israel, its first market, in March 2005, Azilect® is now marketed in the US, Canada, Israel, the EU and Turkey.

API - Supplying the world with healthy ingredients

In addition to the production and sale of finished pharmaceutical products, Teva is a leading global supplier of Active Pharmaceutical Ingredients, the vital raw materials of the drug manufacturing industry.
On top of supplying a major share of Teva's own needs, the TAPI (Teva Active Pharmaceutical Ingredients) division is an active competitor in world markets, investing both in the development of new products and manufacturing processes and in the upgrading of production facilities. It also provides an essential link in Teva's strategic marketing chain. The division often spearheads the company's entry into new drug markets, providing a cost effective source of materials with which to commence local manufacturing and establishing viable distribution channels.
TAPI equips its production facilities with cutting-edge technologies and state-of-the art computerized systems to maintain its consistently high product quality, while continuously improving productivity and reliability. For over 70 years, quality has been the cornerstone upon which TAPI is built, enabling us to consistently deliver top quality products and services. Visit Teva's API division website and learn more about us and our activities at www.tapi.com